Abstract
While now commonly applied for studying human brain function the value of functional magnetic resonance imaging in drug development has only recently been recognized. Here we describe the different functional magnetic resonance imaging techniques applied in Alzheimer’s disease drug development with their applications, implementation guidelines, and potential pitfalls.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kapur S, Zipursky RB, Remington G et al (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155(7):921–928. https://doi.org/10.1176/ajp.155.7.921
Nordstrom AL, Farde L, Wiesel FA et al (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33(4):227–235
Borsook D, Becerra L, Hargreaves R (2006) A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 5(5):411–424. https://doi.org/10.1038/nrd2027
Logothetis NK (2008) What we can do and what we cannot do with fMRI. Nature 453(7197):869–878. https://doi.org/10.1038/nature06976
Okon-Singer H, Mehnert J, Hoyer J et al (2014) Neural control of vascular reactions: impact of emotion and attention. J Neurosci 34(12):4251–4259. https://doi.org/10.1523/JNEUROSCI.0747-13.2014
Van Dijk KR, Sabuncu MR, Buckner RL (2012) The influence of head motion on intrinsic functional connectivity MRI. NeuroImage 59(1):431–438. https://doi.org/10.1016/j.neuroimage.2011.07.044
Volkow ND, Wang GJ, Fowler JS et al (2003) Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl) 166(3):264–270. https://doi.org/10.1007/s00213-002-1340-7
Fusar-Poli P, Smieskova R, Kempton MJ et al (2013) Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 37(8):1680–1691. https://doi.org/10.1016/j.neubiorev.2013.06.001
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Holiga, S., Abdulkadir, A., Klöppel, S., Dukart, J. (2018). Functional Magnetic Resonance Imaging in Alzheimer’ Disease Drug Development. In: Perneczky, R. (eds) Biomarkers for Alzheimer’s Disease Drug Development. Methods in Molecular Biology, vol 1750. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7704-8_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7704-8_10
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7703-1
Online ISBN: 978-1-4939-7704-8
eBook Packages: Springer Protocols